Axa S.A. Allogene Therapeutics, Inc. Transaction History

Axa S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $128,199 - $190,742	28,300 New	28,300 $140,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $1.9 Million - $3.75 Million	337,400 New	337,400 $2.12 Million
Q4 2019 Feb 18, 2020	SELL	$24.82 - $31.4 $4.26 Million - $5.39 Million	-171,755 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $7,911 - $9,995	-303 Reduced 0.18%	171,755 $4.68 Million
Q2 2019 Aug 13, 2019	BUY	$25.56 - $31.09 $1.76 Million - $2.14 Million	68,773 Added 66.59%	172,058 $4.62 Million
Q1 2019 May 14, 2019	BUY	$24.82 - $32.54 $2.56 Million - $3.36 Million	103,285 New	103,285 $2.99 Million

166

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $217M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.